Gossamer bio announces first quarter 2021 financial results and provides corporate update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter of 2021 and provided a corporate update. clinical-stage product candidate updates seralutinib (gb002): inhaled pdgfr, csf1r and c-kit inhibitor for pah enrollment ongoing in the torrey study,
GOSS Ratings Summary
GOSS Quant Ranking